Relevant bibliographies by topics / Anti-breast cancer drug

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Anti-breast cancer drug'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anti-breast cancer drug.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anti-breast cancer drug"

1

Lou, Song. "Multifunctional Nanotherapeutics for Drug-Resistant Breast Cancer." Bioequivalence & Bioavailability International Journal 6, no. 1 (2022): 1–6. http://dx.doi.org/10.23880/beba-16000160.

Full text
Abstract:
Tumors are inherently resilient and always develop drug-resistance, leading to poor patient therapy effect. With the developing of sophisticated analytical tools, some novel strategy on improving targeting of anti-cancer delivery is developed to better thwart drug-resistance. This report demonstrates a multilayered nano-system to serve as a multifunctional platform for the treatment of drug-resistant breast cancers. This nano-system is composed of a poly (lactic-co-glycolic acid) core, a liposome second layer, and a hyaluronic acid outmost layer. The different types of drug, loaded in differen
APA, Harvard, Vancouver, ISO, and other styles
2

Hussain, Tanveer, Seeram Ramakrishna, and Sharjeel Abid. "Nanofibrous drug delivery systems for breast cancer: a review." Nanotechnology 33, no. 10 (2021): 102001. http://dx.doi.org/10.1088/1361-6528/ac385c.

Full text
Abstract:
Abstract Breast cancer is the most common type of cancer among women. Breast-conserving surgery (BCS) is one of the preferred approaches for treating non-invasive or early-stage breast cancers. However, local-regional recurrence (LRR) is one of the critical risk factors after BCS. As many as 10%–20% of BCS cases may show LRR within 5 years and almost 50% within 10 years after surgery. Radiation therapy is one of the preferred treatments used to prevent LRR after BCS. However, because of possible side-effects of radiation therapy, targeted drug delivery systems (DDS) based on nanofibers loaded
APA, Harvard, Vancouver, ISO, and other styles
3

Cai, Alvan, Yuan Chen, Lily S. Wang, John K. Cusick, and Yihui Shi. "Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer." Cancers 16, no. 15 (2024): 2635. http://dx.doi.org/10.3390/cancers16152635.

Full text
Abstract:
HER2 (human epidermal growth factor receptor 2) is highly expressed in a variety of cancers, including breast, lung, gastric, and pancreatic cancers. Its amplification is linked to poor clinical outcomes. At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequently mutated or amplified in cancers, thus spurring extensive research into HER2 modulation and inhibition as viable anti-cancer strategies. An impressive body of FDA-approved drugs, including anti-HER2 monoclonal antibodies (mAbs), antibody–drug conjugates
APA, Harvard, Vancouver, ISO, and other styles
4

Bernatsky, S., R. Ramsey-Goldman, M. Petri, et al. "Breast cancer in systemic lupus." Lupus 26, no. 3 (2016): 311–15. http://dx.doi.org/10.1177/0961203316664595.

Full text
Abstract:
Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE durat
APA, Harvard, Vancouver, ISO, and other styles
5

Ton Tai, Dinh Xuan, Le Thi Huong, Tran Hoang Mai, Vu Manh Hung, Nguyen Thi Huyen, and Bui Thanh Tung. "Screening in silico the human epidermal growth factor receptor-2inhibitory effect of isoflavones by molecular docking method for their potential use in breast cancer." Ministry of Science and Technology, Vietnam 65, no. 2 (2023): 47–53. http://dx.doi.org/10.31276/vjste.65(2).47-53.

Full text
Abstract:
Isoflavones are secondary phenolic metabolites found in most legumes. These compounds have important pharmacological significance such as anti-osteoporosis, anti-aging, and anti-cancer properties. Breast cancer is one of the most common cancers in women worldwide. Human epidermal growth factor receptor-2 (HER2) is an important target in breast cancer treatment. In this study, we evaluated the ability of sixty isoflavones compounds to inhibit the HER2 enzyme for their potential use in breast cancer treatments by the molecular docking method. Molecular docking was done by Autodock vina software.
APA, Harvard, Vancouver, ISO, and other styles
6

Samuel, Samson, Elizabeth Varghese, Peter Kubatka, Chris Triggle, and Dietrich Büsselberg. "Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer." Biomolecules 9, no. 12 (2019): 846. http://dx.doi.org/10.3390/biom9120846.

Full text
Abstract:
Interest has grown in studying the possible use of well-known anti-diabetic drugs as anti-cancer agents individually or in combination with, frequently used, chemotherapeutic agents and/or radiation, owing to the fact that diabetes heightens the risk, incidence, and rapid progression of cancers, including breast cancer, in an individual. In this regard, metformin (1, 1-dimethylbiguanide), well known as ‘Glucophage’ among diabetics, was reported to be cancer preventive while also being a potent anti-proliferative and anti-cancer agent. While meta-analysis studies reported a lower risk and incid
APA, Harvard, Vancouver, ISO, and other styles
7

Li, Jiaying, Guowei Zhang, and Hongxia Yang. "Optimal modeling of anti breast cancer drug candidates." Highlights in Science, Engineering and Technology 45 (April 18, 2023): 350–60. http://dx.doi.org/10.54097/hset.v45i.7573.

Full text
Abstract:
As breast cancer is one of the most common cancers with high mortality rate in the world, this paper studies the optimal screening of anti-breast cancer candidate drugs. First, the data of 729 compound molecular descriptors are preprocessed, rough cleaned and filtered to 253, and then the cluster feature tree and correlation analysis are used to further reduce the dimension of data redundancy information, and 29 representative molecular descriptors are screened. In order to determine the importance and significance variables affecting the activity of compounds, the preliminary results were obt
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Ya-Zhou, Hai-Lin Liu, Qian-Song He, and Zhi Xu. "The In Vitro Anticancer Activity and Potential Mechanism of Action of 1-[(1R,2S)-2-fluorocyclopropyl]Ciprofloxacin-(4-methyl/phenyl/benzyl-3- aryl)-1,2,4-triazole-5(4H)-thione Hybrids." Current Topics in Medicinal Chemistry 20, no. 16 (2020): 1493–98. http://dx.doi.org/10.2174/1568026620666200310123723.

Full text
Abstract:
Aims: Development of 1-[(1R, 2S)-2-fluorocyclopropyl]ciprofloxacin-1,2,4-triazole-5(4H)- thione hybrids as potential dual-acting mechanism anticancer agent to overcome the drug resistance. Background: Chemotherapy is an essential tool for the treatment of lung and female breast cancers, and numerous anticancer agents have been launched for this purpose. However, the clinical outcomes of chemotherapy are usually far from satisfactory due to the side effects and resistance to chemotherapeutic drugs. Thus, it is urgent to develop novel anti-lung and anti-breast cancer agents. Background: Chemothe
APA, Harvard, Vancouver, ISO, and other styles
9

Rajagopal, Kalirajan, Anandarajagopal Kalusalingam, Anubhav Raj Bharathidasan, et al. "In Silico Drug Design of Anti-Breast Cancer Agents." Molecules 28, no. 10 (2023): 4175. http://dx.doi.org/10.3390/molecules28104175.

Full text
Abstract:
Cancer is a condition marked by abnormal cell proliferation that has the potential to invade or indicate other health issues. Human beings are affected by more than 100 different types of cancer. Some cancer promotes rapid cell proliferation, whereas others cause cells to divide and develop more slowly. Some cancers, such as leukemia, produce visible tumors, while others, such as breast cancer, do not. In this work, in silico investigations were carried out to investigate the binding mechanisms of four major analogs, which are marine sesquiterpene, sesquiterpene lactone, heteroaromatic chalcon
APA, Harvard, Vancouver, ISO, and other styles
10

Cao, Yi, Yunjin Li, Ruijie Liu, Jianhua Zhou, and Kuansong Wang. "Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer." Cancers 15, no. 9 (2023): 2568. http://dx.doi.org/10.3390/cancers15092568.

Full text
Abstract:
The amplification of epidermal growth factor receptor 2 (HER2) is associated with a poor prognosis and HER2 gene is overexpressed in approximately 15–30% of breast cancers. In HER2-positive breast cancer patients, HER2-targeted therapies improved clinical outcomes and survival rates. However, drug resistance to anti-HER2 drugs is almost unavoidable, leaving some patients with an unmet need for better prognoses. Therefore, exploring strategies to delay or revert drug resistance is urgent. In recent years, new targets and regimens have emerged continuously. This review discusses the fundamental
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anti-breast cancer drug"

1

Yaourtis, Andria. "Innate and anti-cancer drug-induced morphological changes in the human breast cancer cell line MDA-MB-231." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/26409.

Full text
Abstract:
Phenotypic changes in tumour cells is a well-established phenomenon and can happen either naturally or in response to a drug. Such changes in phenotype are often accompanied with changes in the behaviour of tumour cells, including growth, proliferation, as well as their migratory and invasive capacity. Phenotypic changes can, therefore, impact the aggressiveness of the tumour cell and dictate their metastatic potential. Thus, it is of utmost importance to fully understand and characterise phenotypic changes in tumour cells in order to better understand tumour progression and identify therapeut
APA, Harvard, Vancouver, ISO, and other styles
2

Guardia, Valenzuela Cristina 1990. "Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer." Doctoral thesis, Universitat Pompeu Fabra, 2019. http://hdl.handle.net/10803/668327.

Full text
Abstract:
El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el pronóstico de esta enfermedad. De manera más reciente, otro Mab llamado pertuzumab, ha mejorado todavía más la eficiencia de trastuzumab. Aún y así, no todas las pacientes se beneficiarán de esta combinación de mAbs. Una proporción de estas pacientes no se beneficiarán de estas terapias anti-HER2, y fallecerán a causa de la presencia o el desarrollo de mecanismos de resistencia. Los tumores con
APA, Harvard, Vancouver, ISO, and other styles
3

Lovitt, Carrie Jade. "Exploring Breast Cancer Drug Targets in the Third Dimension with Imaging." Thesis, Griffith University, 2014. http://hdl.handle.net/10072/367232.

Full text
Abstract:
This project utilises innovative methodology to evaluate the suitability of novel three-dimensional (3D) cell culture models for investigating anti-cancer drug activity. 3D cell culture methodology was utilised as this in vitro approach is considered to recapitulate the in vivo conditions more accurately than two-dimensional (2D) monolayer cell culture. Two separate 3D cell culture model formats were developed which are amenable to automated liquid handling systems, and a variety of instruments for total well fluorescence and confocal imaging. The first 3D cell culture assay developed was in a
APA, Harvard, Vancouver, ISO, and other styles
4

Bonzi, Gwénaëlle A. M. "Novel polysaccharide anti-tumour drug delivery system for active targeting and controlled release to breast cancer bone metastases." Doctoral thesis, Università degli studi di Padova, 2014. http://hdl.handle.net/11577/3423664.

Full text
Abstract:
ABSTRACT In the late stage of the disease, breast cancer patients often develop bone metastases, a major cause of cancer-related death among women worldwide. The common treatment currently used clinically includes the anti-neoplastic agent paclitaxel combined with the bisphosphonate alendronate. Paclitaxel is an anti-neoplastic drug which cytotoxic effect is mainly attributed to its ability to promote the assembly of microtubules as well as prevent the depolymerisation of these microtubules. Stabilization of the microtubule networks stops mitotic functions that, in sequence, blocks cell div
APA, Harvard, Vancouver, ISO, and other styles
5

Wan, Xiao. "Development of advanced three-dimensional tumour models for anti-cancer drug testing." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:5342fe46-c676-4fe8-8b6e-96d17a18d17d.

Full text
Abstract:
Animal testing is still the common method to test the efficacy of new drugs, but tissue engineered in vitro models are becoming more acceptable for replacing and reducing animal testing in anti-cancer drug screening by developing in vitro three-dimensional (3D) tumour models for anti-cancer drug testing. In this study, three-dimensional (3D) culture methods were developed to mimic the tumour microenvironment. 3D culturing is to seed, maintain and expand cultured cells in three-dimensional space, in contrast to the traditional two-dimensional (2D) method in which the cells attach to the bottom
APA, Harvard, Vancouver, ISO, and other styles
6

Leonardi, Antonio. "Design, synthesis of substituted purines, phenylpyrrolidine derivatives, cyclic and acyclic bis (p-nitrobenzenesulfonamides), and in vitro anti-cancer activity against lung, breast and prostate cell lines." Doctoral thesis, Università di Catania, 2012. http://hdl.handle.net/10761/1175.

Full text
Abstract:
Al momento sono stati classificati più di 100 forme di cancro secondo il tipo di cellula inizialmente affetta. Le patologie tumorali sono caratterizzate da una crescita cellulare incontrollata che porta alla formazione di grumi o masse di tessuto che danneggiano l organismo. Lo sviluppo di nuovi farmaci antitumorali è una delle attività prioritarie nell'ambito della ricerca chimico-farmaceutica, non solo per l alta incidenza ma anche per i numerosi inconvenienti legati ai farmaci in uso. Il progetto di ricerca è stato indirizzato al disegno, sintesi e valutazione biologica di nuovi farmaci ant
APA, Harvard, Vancouver, ISO, and other styles
7

Dubois, Clémence. "Optimisation du traitement du cancer du sein Triple-Négatif : développement des modèles de culture cellulaire en trois dimensions, efficacité de l'Olaparib (anti-PARP1) en combinaison avec la radiothérapie et chimiorésistance instaurée par les protéines Multi Drug Résistance." Thesis, Université Clermont Auvergne‎ (2017-2020), 2018. http://www.theses.fr/2018CLFAS018/document.

Full text
Abstract:
Le cancer du sein est une maladie complexe et difficile à caractériser. Parmi les différents sous-types moléculaires, les tumeurs du sein Triple-Négatives (TN) sont particulièrement agressives et de mauvais pronostic. Elles sont caractérisées par une absence d’expression des récepteurs aux œstrogènes (ER), à la progestérone (PR), l’absence de surexpression du récepteur Human Epidermal growth factor 2 (HER2) et de fréquentes mutations sur les gènes BRCA1/2 (profil « BRCAness »). En absence de thérapies ciblées efficaces, de nombreux traitements ciblés notamment les inhibiteurs de poly-ADP-ribos
APA, Harvard, Vancouver, ISO, and other styles
8

Khubieh, J. "Immunoassay of 4-Hydroxyandrostenedione, a new anti-cancer agent." Thesis, University of Surrey, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.234454.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Diaz-Cruz, Edgar S. "Interrelationships between aromatase and cyclooxygenase-2 and their role in the autocrine and paracrine mechanisms in breast cancer." Connect to resource, 2005. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1117117648.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Oechsle, Crystal Mae. "The Use and Enhancement of Anti-Cancer Vaccine Therapy with Low-Toxicity Drugs for the Treatment of HER2 Positive Breast Cancer." Kent State University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=kent1561121654968093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Anti-breast cancer drug"

1

Julia, Gee, Nicholson Robert I, and SpringerLink (Online service), eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Springer Netherlands, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hiscox, Stephen, Julia Gee, and Robert I. Nicholson, eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer. Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-1-4020-8526-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hiscox, Stephen, Julia Gee, and Robert I. Nicholson. Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Hiscox Stephen Gee Julia Nicholson Robert I, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gluckman, Sir Peter, Mark Hanson, Chong Yap Seng, and Anne Bardsley. Guidelines for breastfeeding and weaning. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198722700.003.0038.

Full text
Abstract:
Breastfeeding provides almost all of the nutrient requirements for the growing infant to the age of 6 months. Complementary foods rich in iron should be introduced by 6 months, but continued breastfeeding past this point is still beneficial to the infant. It is also beneficial for the mother, reducing postpartum weight retention and lowering the risk of breast and other gynaecological cancers. Breastfeeding women have increased energy requirements to meet the energy costs of milk production. Some specific nutrient requirements also increase during lactation. Excess alcohol consumption, smoking
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Anti-breast cancer drug"

1

Priya, R. Arul, K. Saravanan, and Chukwuebuka Egbuna. "Phytochemical Investigation and Evaluation of Anti-Breast Cancer Activity of Chloroform Extract of Tagetes erecta." In Drug Development for Cancer and Diabetes. Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429330490-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Domenici, Giacomo, Gonçalo Trindade, Marta F. Estrada, et al. "Patient-Derived Breast Cancer Tissue Cultures for Anti-Endocrine Drug Assays." In Methods in Molecular Biology. Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2513-2_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gao, Wentao, Ziyi Huang, Hao Zhang, and Jianfeng Lu. "Anti-breast Cancer Drug Design and ADMET Prediction of ERa Antagonists Based on QSAR Study." In Intelligent Computing Theories and Application. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-13829-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nagar, Swati. "Pharmacokinetics of Anti-Cancer Drugs Used in Breast Cancer Chemotherapy." In Chemo Fog. Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6306-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Natarajan, Karthika, Maria R. Baer, and Douglas D. Ross. "Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-09801-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Harris, Randall E. "Epidemiology of Breast Cancer and Nonsteroidal Anti-Inflammatory Drugs." In COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-302-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kaye, S. B. "The Multi-Drug Resistance Phenotype and its Reversal by Drugs (with Special Emphasis on Anti-Oestrogens)." In Endocrine Therapy of Breast Cancer V. Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77662-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hyder, Salman M., Benford Mafuvadze, and Cynthia Besch-Williford. "Novel Anti-angiogenic Therapies Using Naturally Occurring and Synthetic Drugs to Combat Progestin-Dependent Breast Cancer." In Cell and Molecular Biology of Breast Cancer. Humana Press, 2013. http://dx.doi.org/10.1007/978-1-62703-634-4_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Abou-Issa, Hussein M., Galal A. Alshafie, and Randall E. Harris. "Chemoprevention of Breast Cancer by Nonsteroidal Anti-Inflammatory Drugs and Selective COX-2 Blockade in Animals." In COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-302-6_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jha, Tarun, Nilanajn Adhikari, Amit Kumar Halder, and Achintya Saha. "Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer." In Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-8136-1.ch011.

Full text
Abstract:
Aromatase is a multienzyme complex overexpressed in breast cancer and responsible for estrogen production. It is the potential target for designing anti-breast cancer drugs. Ligand and Structure-Based Drug Designing approaches (LBDD and SBDD) are involved in development of active and more specific Nonsteroidal Aromatase Inhibitors (NSAIs). Different LBDD and SBDD approaches are presented here to understand their utility in designing novel NSAIs. It is observed that molecules should possess a five or six membered heterocyclic nitrogen containing ring to coordinate with heme portion of aromatase
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anti-breast cancer drug"

1

Marshall, Lauren, Isabel Löwstedt, Paul Gatenholm, and Joel Berry. "Prevascularized, Co-Culture Model for Breast Cancer Drug Development." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80409.

Full text
Abstract:
The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of w
APA, Harvard, Vancouver, ISO, and other styles
2

"PAMAM Dendrimers as anti-HER2 Positive Breast Cancer Treatment." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0176.

Full text
Abstract:
Background: Poly (amidoamine) dendrimers (PAMAMs) are widely used in drug delivery systems and gene transfection as drug carriers. They also exert several biological effects like modulating gene expression, particularly EGFR (ErbB1) signaling pathway, which raises the question of whether these polymers can also inhibit the phosphorylation of HER2 (ErbB2) in breast cancer. However, this area hasn’t been investigated before. Methods: In this study, we evaluated the anticancer effects of different generations and surface chemistries of PAMAMs on HER2 positive breast cancer cells (SkBr3 and ZR-75
APA, Harvard, Vancouver, ISO, and other styles
3

Lichtenfels, Martina, Camila Alves Silva, Caroline Brunetto Farias, Alessandra Borba Anton Souza, and Antônio Luiz Frasson. "TIN VITRO BREAST CANCER CHEMORESISTANCE TEST." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1058.

Full text
Abstract:
Introduction: Tumor resistance is the main cause of treatment failure leading to cancer progression and is classified into intrinsic and acquired resistance. Intrinsic resistance is related to a preexisting condition and acquired resistance is induced by a drug. Some methods are already available worldwide to assess drug resistance, however, in Brazil no in vitro chemoresistance test for cancer is validated for clinic use. Objectives: The aim of our study was to validate the in vitro chemoresistance test Chemobiogram for the drugs used in breast cancer (BC) treatment. An incomplete response to
APA, Harvard, Vancouver, ISO, and other styles
4

Al-Atieh, Noor, Salma Ahmad, Hanan Nazar, and Allal Ouhtit. "Anti-cancer properties of Microalgae (T1) Extract in Breast Cancer Cell Lines." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0154.

Full text
Abstract:
Breast cancer (BC), a worldwide health issue, is the most common malignant cancer in women in Gulf region, including the State of Qatar. Unfortunately, malignant tumors has the capability to metastasis, which involves both migration and invasion of cancer cells which are the most threatening aspects of cancer (McSherry et al., 2007). Consequently, researchers have concentrated on Complementary and Alternative medicine (CAM) modalities, as conventional medicine has been facing various challenges such as; poor understanding of the mechanisms with BC proliferation and invasion within various grou
APA, Harvard, Vancouver, ISO, and other styles
5

Xiao, Weiqiang, Xiaoli Chai, Shengji Jiang, and Zhibai Huang. "Optimization modeling of anti breast cancer drug candidates based on data mining." In International Symposium on Robotics, Artificial Intelligence, and Information Engineering (RAIIE 2022), edited by Johan Debayle. SPIE, 2022. http://dx.doi.org/10.1117/12.2658192.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hu, Xinxin, and Jiayao Lv. "Optimized modeling of anti-breast cancer drug candidates based on machine learning." In Second International Conference on Biomedical and Intelligent Systems (IC-BIS2023), edited by Ming Chen and Gangmin Ning. SPIE, 2023. http://dx.doi.org/10.1117/12.2687762.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jácome, María Amalia, Ana López-Cheda, and Samuel Saavedra. "Estimation of Cardiotoxicity in Breast Cancer Patients Using Presmoothing and Cure Models." In VII Congreso XoveTIC: impulsando el talento científico. Servizo de Publicacións. Universidade da Coruña, 2024. https://doi.org/10.17979/spudc.9788497498913.65.

Full text
Abstract:
Breast cancer is the most common type of cancer for women. Nowadays, the side-effects that some treatments against this type of cancer can be a major problem. One example of this is HER2-positive breast cancer patients. Patients are prescribed trastuzumab, a drug with anti-tumour efficacy, but this treatment can cause various undesirable effects such as heart problems, known as cardiotoxicity. With the aim of improving the quality of life of those affected, the question is clear: what is the likelihood of suffering cardiotoxicity? In this work, this probability is estimated using a new approac
APA, Harvard, Vancouver, ISO, and other styles
8

Rudkouskaya, Alena, Jason T. Smith, Marien Ochoa, Xavier Intes, and Margarida Barroso. "Quantification of anti-HER2 drug uptake into human breast cancer cells using fluorescence lifetime FRET imaging." In Visualizing and Quantifying Drug Distribution in Tissue IV, edited by Conor L. Evans and Kin Foong Chan. SPIE, 2020. http://dx.doi.org/10.1117/12.2544429.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Barbosa, Ana Carolina Silva, Cristiano Augusto Andrade de Resende, Henrique Carvalho Rocha, and Andreza Karine de Barros Almeida Souto. "Case report: sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine in breast cancer." In Brazilian Breast Cancer Symposium 2024. Mastology, 2024. http://dx.doi.org/10.29289/259453942024v34s1104.

Full text
Abstract:
Objective: Trastuzumab emtansine (T-DM1) is an anti-HER2 antibody-drug conjugate indicated for the treatment of HER2- positive breast cancer. One of the most severe adverse events reported with T-DM1 is hepatotoxicity. More recently, some cases of noncirrhotic portal hypertension have been described in patients with long-term T-DM1. The underlying liver condition is usually sinusoidal obstruction syndrome. Methodology: Here, we present the case of a patient with early-stage HER2-positive breast cancer who received adjuvant T-DM1 and developed hepatotoxicity due to this condition. Results: We r
APA, Harvard, Vancouver, ISO, and other styles
10

Mladenović, Milan P., Nevena M. Tomašević, Sanja Lj Matić, Tamara M. Mladenović, and Rino Ragno. "Computer-aided design of new drugs against breast cancer." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.641m.

Full text
Abstract:
Computational medicinal chemistry, if used properly and in accordance with the available experimental data, may provide significant support to rational drug design. Herein, an overview of the computational approaches that have been applied to an estrogen receptor α (ERα) and endowed in the rational design of pM ERα antagonists with profound anti-breast cancer activity either in vitro or in vivo, will be presented. ERα is a 17β-estradiol inducible transcriptional regulator that initiates the RNA polymerase II-dependent transcriptional machinery, pointed for breast cancer (BC) development via ei
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Anti-breast cancer drug"

1

Gaczynska, Maria E. Molecular Characteristics of Multicorn, A New Large Proteolytic Assembly and Potential Anti-Cancer Drug Target, in Human Breast Cancer Cells. Defense Technical Information Center, 2003. http://dx.doi.org/10.21236/ada418003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yen, Timothy J. Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada439249.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yen, Timothy J. Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs. Defense Technical Information Center, 2002. http://dx.doi.org/10.21236/ada407481.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yen, Timothy J. Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada428246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anti-breast cancer drug' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography